Related Experiment Video

Updated: Jul 15, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Dawn of Aurora kinase inhibitors as anticancer drugs

Sheila A Doggrell1

  • 1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz

Expert Opinion on Investigational Drugs
|August 28, 2004
PubMed

Insights

VX-680, a novel drug, shows promise in treating acute myelogenous leukemia (AML) by inhibiting Aurora kinases. This compound effectively reduced leukemia cell growth and tumors in preclinical studies, offering hope for better AML therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Acute myelogenous leukemia (AML) has a poor prognosis, with only 25% of patients surviving beyond 5 years with current standard chemotherapy.
  • Aurora kinases are frequently overexpressed in various human cancers, suggesting their potential as therapeutic targets.

Purpose of the Study:

  • To investigate the efficacy of VX-680, an inhibitor of Aurora kinases, in preclinical models of acute myelogenous leukemia (AML).
  • To evaluate the inhibitory effects of VX-680 on Aurora kinase family members and FMS-like tyrosine kinase-3 (FLT3).

Main Methods:

  • VX-680's inhibitory activity was assessed against Aurora-A, -B, -C, and FLT3 using biochemical assays.
  • The drug's effect on colony formation was evaluated in primary AML cells resistant to standard therapies.
  • Antitumor efficacy of VX-680 was examined in nude mice bearing human AML xenografts.

Main Results:

  • VX-680 demonstrated potent inhibition of Aurora kinases (A, B, C) and FLT3 with nanomolar inhibitory constants.
  • The compound significantly inhibited colony formation in primary AML cells refractory to conventional treatments.
  • VX-680 treatment led to a marked reduction in human AML tumor growth in vivo.

Conclusions:

  • VX-680 exhibits significant preclinical efficacy against AML by targeting Aurora kinases and FLT3.
  • The findings support the continued development of VX-680 as a potential therapeutic agent for acute myelogenous leukemia.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...